Alkermes plc (ALKS)

Market Cap	4.13B
Revenue (ttm)	1.66B
Net Income (ttm)	355.76M
Shares Out	167.08M
EPS (ttm)	2.10
PE Ratio	11.73
Forward PE	8.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	433,952
Open	24.55
Previous Close	24.44
Day's Range	24.30 - 24.77
52-Week Range	22.01 - 33.71
Beta	0.55
Analysts	Buy
Price Target	35.11 (+42.15%)
Earnings Date	May 1, 2024

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 16, 1991
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: ALKS

Analyst Forecast

According to 10 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $35.11, which is an increase of 42.15% from the latest price.

Price Target

$35.11

(42.15% upside)

Analyst Consensus: Buy